Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ACP1 | P24666 | 5/20 | 0.47 |
| ▸ | PTPN12 | Q05209 | 3/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.47 |
| ▸ | PTPN13 | Q12923 | 2/20 | 0.47 |
| ▸ | SSU72 | Q9NP77 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912818 | 1.00 | SRC (1.00) | SRCLMNAMAPK1PTPN1PTPN6 | |
| SCHEMBL11166146 | 1.00 | SRC (1.00) | SRCLMNAMAPK1PTPN1PTPN6 | |
| SCHEMBL5016643 | 0.98 | SRC (0.96) | SRCLMNAMAPK1PTPN1PTPN6 | |
| SCHEMBL28406293 | 0.98 | SRC (0.96) | SRCLMNAMAPK1PTPN1PTPN6 | |
| SCHEMBL28403215 | 0.98 | SRC (0.96) | SRCLMNAMAPK1PTPN1PTPN6 | |
| SCHEMBL18289927 | 0.88 | SRC (0.78) | SRCLMNAMAPK1PTPN1PTPN6 | |
| SCHEMBL28406331 | 0.86 | SRC (0.73) | SRCLMNAMAPK1PTPN1PTPN6 | |
| SCHEMBL11057978 | 0.84 | SRC (0.73) | SRCLMNAMAPK1PTPN1PTPN6 | |
| SCHEMBL8121173 | 0.83 | SRC (0.70) | SRCLMNAMAPK1PTPN1PTPN6 | |
| SCHEMBL10671823 | 0.83 | SRC (0.70) | SRCLMNAMAPK1PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | GLADIUS PHARMACEUTICALS INC (CA) | 2019-04-04 | — | — | US | disclosed |
| CN-106317075-A | Preparing method of Cefsulodin | 中国医药集团总公司四川抗菌素工业研究所 | 2017-01-11 | — | — | CN | disclosed |
| CN-104910179-A | Preparation method of sulbenicillin sodium for injection | HUNAN ER KANG XIANGYAO PHARMACEUTICAL COMPANY | 2015-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | PGLS, GNE, COMT | SRC 3751/4885LMNA 681/4885MAPK1 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.